APA (7th ed.) Citation

T, K., E, W., J, O., DE, R., W, X., M, S., . . . F, P. (2026). Serum GFAP and NfL augment a metabolomics-driven strategy for long-term prediction of multiple sclerosis progression. Communications medicine, 6(1), . https://doi.org/10.1038/s43856-026-01453-5

Chicago Style (17th ed.) Citation

T, Kacerova, et al. "Serum GFAP and NfL Augment a Metabolomics-driven Strategy for Long-term Prediction of Multiple Sclerosis Progression." Communications Medicine 6, no. 1 (2026). https://doi.org/10.1038/s43856-026-01453-5.

MLA (9th ed.) Citation

T, Kacerova, et al. "Serum GFAP and NfL Augment a Metabolomics-driven Strategy for Long-term Prediction of Multiple Sclerosis Progression." Communications Medicine, vol. 6, no. 1, 2026, https://doi.org/10.1038/s43856-026-01453-5.